Takeda and 3M Target HPV and Future Growth
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 58 (Table of Contents)
Published: 1 Apr-2005
DOI: 10.3833/pdr.v2005.i58.693 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
By signing up Takeda Pharmaceutical to co-develop and market jointly one of its proprietary immune response modifiers (IRMs) for high-risk human papillomavirus (HPV) infection and cervical dysplasia, 3M is aiming to commercialise a follow-up to the successful Aldara#174; Cream 5% (imiquimod)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS